Under construction – not a live service
Sign in
CompletedPhase 1

Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

Key facts

Phase
Phase 1

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

Trial details

Who runs it
Hutchmed Ltd.
Trial code
EU 2023-508819-23-00
Record updated
30 January 2025